Customised Services in Preclinical Inflammation

Publicerad 2016-05-12


Since May 1st Malin Hultqvist Hopkins, former CSO, is appointed CEO of Redoxis. This change is in line with Redoxis continuous ambition to be a focused and efficient CRO specialising on preclinical autoimmune and inflammatory models in vitro and in vivo.

Former CEO, Peter Olofsson, is since April 1st CEO of Redoxis R&D focused subsidiary ProNoxis AB and will continue late stage preclinical development of therapies for severe and rare autoimmune diseases.

This is a result from a strategic decision, anticipated to be beneficial for both companies with more focused and engaged development. 

Naturally, we will maintain strong collaboration and synergistic R&D capacities between the companies.